Literature DB >> 30300894

Favorable Outcomes of Elderly ABO-Incompatible Kidney Transplantation-Pilot Single Center Experience.

Akihiro Kosoku1, Junji Uchida2, Kazuya Kabei1, Shunji Nishide1, Hisao Shimada1, Tomoaki Iwai1, Nobuyuki Kuwabara1, Toshihide Naganuma1, Keiko Maeda3, Norihiko Kumada4, Yoshiaki Takemoto1, Tatsuya Nakatani1.   

Abstract

BACKGROUND: The growth in the end-stage kidney disease (ESKD) population has been predominantly in the older adult population. In Japan, ABO-incompatible kidney transplantation has become an acceptable treatment option. However, few studies have been conducted on elderly ABO-incompatible kidney transplantation. PATIENTS AND METHODS: Seventeen patients aged 60 years and older who received their grafts from ABO-incompatible living donors at our institution between December 2006 and September 2016 were enrolled in this study, and the outcome of these recipients was evaluated.
RESULTS: All 17 patients underwent successful kidney transplantation. Both overall patient and graft survival rates were 100, 100, and 83.3% at posttransplant 1, 3, and 5 years respectively. Six of the 17 patients (35.3%) had an episode of biopsy-proven acute cellular rejection. Two patients who developed steroid- and deoxyspergualin-resistant acute rejection required anti-human thymocyte immunoglobulin.
CONCLUSION: ABO-incompatible kidney transplantation may be an effective radical renal replacement therapy for elderly patients with ESKD, although it could be a high-risk procedure.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  ABO-incompatible; Elderly; Kidney transplantation

Mesh:

Substances:

Year:  2018        PMID: 30300894     DOI: 10.1159/000492721

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  1 in total

Review 1.  Latest insights on ABO-incompatible living-donor renal transplantation.

Authors:  Junji Uchida; Akihiro Kosoku; Toshihide Naganuma; Tomoaki Tanaka; Tatsuya Nakatani
Journal:  Int J Urol       Date:  2019-09-14       Impact factor: 3.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.